OBJECTIVES: USPIO (ultrasmall superparamagnetic iron oxide contrast agent) MRI was a promising imaging modality in the detection of lymph-node metastases. And this meta-analysis is performed to compare the diagnostic accuracy of USPIO-enhanced MRI with non-enhanced MRI, USPIO-enhanced MRI in various body regions, and postcontrast alone for diagnosis of lymph-node metastases. METHODS: A comprehensive and systematic search was conducted in PubMed and EMBASE databases. After a systematic review of the studies, sensitivity, specificity, the Q* value and other measures of accuracy of USPIO-enhanced MRI in the diagnosis of lymph-node metastases were summarized. The overall test performance was based on summary receiver operating characteristic curves. RESULTS: Summary of ROC curve analysis for per-lymph-node data shows a pooled sensitivity of 0.90 (95% confidential interval [CI]: 0.88-0.91) and overall specificity of 0.96 (95% CI: 0.95-0.97) for USPIO-enhanced MRI, the Q* value for USPIO-enhanced MRI is 0.9195, diagnostic odds ratio (DOR) is 162.28 (95% CI: 91.82-286.81). Non-enhanced MRI had less overall sensitivity 0.39 (95% CI: 0.34-0.43) and specificity 0.90 (95% CI: 0.89-0.91), respectively, the Q* value for USPIO-enhanced MRI was 0.6321, DOR is 5.81 (95% CI: 3.64-9.82). Postcontrast MRI alone had sensitivity 0.85 (95% CI: 0.81-0.88) and specificity 0.93 (95% CI: 0.91-0.95), respectively, the Q* value for USPIO-enhanced MRI was 0.8976, DOR is 76.92 (95% CI: 34.21-172.93). There was significant heterogeneity for studies reporting enhanced MRI and non-enhanced MRI. CONCLUSIONS: This meta-analysis has shown that USPIO-enhanced MRI offers higher diagnostic performance than conventional MRI, and is sensitive and specific for the detection of lymph-node metastases. Postcontrast images alone can equate diagnostic performance pre- and postcontrast MRI has achieved for lymph-node characterization. And the role of USPIO-enhanced MRI in clinical practice still needs to be investigated in future studies.
OBJECTIVES: USPIO (ultrasmall superparamagnetic iron oxide contrast agent) MRI was a promising imaging modality in the detection of lymph-node metastases. And this meta-analysis is performed to compare the diagnostic accuracy of USPIO-enhanced MRI with non-enhanced MRI, USPIO-enhanced MRI in various body regions, and postcontrast alone for diagnosis of lymph-node metastases. METHODS: A comprehensive and systematic search was conducted in PubMed and EMBASE databases. After a systematic review of the studies, sensitivity, specificity, the Q* value and other measures of accuracy of USPIO-enhanced MRI in the diagnosis of lymph-node metastases were summarized. The overall test performance was based on summary receiver operating characteristic curves. RESULTS: Summary of ROC curve analysis for per-lymph-node data shows a pooled sensitivity of 0.90 (95% confidential interval [CI]: 0.88-0.91) and overall specificity of 0.96 (95% CI: 0.95-0.97) for USPIO-enhanced MRI, the Q* value for USPIO-enhanced MRI is 0.9195, diagnostic odds ratio (DOR) is 162.28 (95% CI: 91.82-286.81). Non-enhanced MRI had less overall sensitivity 0.39 (95% CI: 0.34-0.43) and specificity 0.90 (95% CI: 0.89-0.91), respectively, the Q* value for USPIO-enhanced MRI was 0.6321, DOR is 5.81 (95% CI: 3.64-9.82). Postcontrast MRI alone had sensitivity 0.85 (95% CI: 0.81-0.88) and specificity 0.93 (95% CI: 0.91-0.95), respectively, the Q* value for USPIO-enhanced MRI was 0.8976, DOR is 76.92 (95% CI: 34.21-172.93). There was significant heterogeneity for studies reporting enhanced MRI and non-enhanced MRI. CONCLUSIONS: This meta-analysis has shown that USPIO-enhanced MRI offers higher diagnostic performance than conventional MRI, and is sensitive and specific for the detection of lymph-node metastases. Postcontrast images alone can equate diagnostic performance pre- and postcontrast MRI has achieved for lymph-node characterization. And the role of USPIO-enhanced MRI in clinical practice still needs to be investigated in future studies.
Authors: Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz Journal: Curr Urol Rep Date: 2014-03 Impact factor: 3.092
Authors: Prashant Chandrasekharan; Zhi Wei Tay; Xinyi Yedda Zhou; Elaine Yu; Ryan Orendorff; Daniel Hensley; Quincy Huynh; K L Barry Fung; Caylin Colson VanHook; Patrick Goodwill; Bo Zheng; Steven Conolly Journal: Br J Radiol Date: 2018-06-21 Impact factor: 3.039
Authors: Peter M Ferguson; Kirk W Feindel; Angela Slocombe; Matthew MacKay; Trudy Wignall; Brett Delahunt; Richard D Tilley; Ian F Hermans Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: Mostafa Atri; Zheng Zhang; Helga Marques; Jeremy Gorelick; Mukesh Harisinghani; Aslam Sohaib; Dow-Mu Koh; Steven Raman; Michael Gee; Haesun Choi; Lisa Landrum; Robert Mannel; Linus Chuang; Jian Qin Michael Yu; Carolyn Kay McCourt; Michael Gold Journal: Eur J Radiol Open Date: 2015